Based on this, we silenced the HIF-1α gene using RNAi to determine the effect of RNAi technology combined with ASP on cancer angiogenesis and provide an experimental basis for comprehensive clinical anticancer therapy using such combinations. Here, HIF1A is linked to cancer.